AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05214833 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Neurofeedback
Description: During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity.
Study NCT06224738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human HER2-targeted CAR-M cells
Description: The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.
Study NCT05514353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-100 Topical Cream
Description: PBI-100 Topical Cream in 1 of 3 dose levels
Study NCT05514353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: The Vehicle Cream formulation contains the same excipients as the active cream
Study NCT05885672 — intervention group
Intervention type: BEHAVIORAL
Intervention: Online psychoeducational lifestyle intervention
Description: A webpage-baed intervention focused on lifestyle interventions that aim to reduce metabolic syndrome severity.
Study NCT06580665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Patients undergo cryoablation.
Study NCT06580665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
Study NCT05072080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvant
Description: CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
Study NCT05072080 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is comprised of formulation buffer
Study NCT06069713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBD advertisements
Description: Participants will view the 5 images of CBD advertisements in their assigned panel and answer questions about their perceptions of the advertisement.
Study NCT05560269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal coaching vs. Constraint based coaching
Description: * 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using verbal cues to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval
Study NCT05560269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal coaching vs. Constraint based coaching
Description: * 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using verbal cues to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval
Study NCT04836013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: combined Lactobacilli
Description: 1 oral stick per day for 30 days starting the day of antibiotic treatment
Study NCT04836013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 oral stick per day for 30 days starting the day of antibiotic treatment
Study NCT06461299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seysara Oral Product
Description: Subjects with a clinical diagnosis of POD will be given sarecycline for four weeks. Dosing of sarecycline will be weight based, either 60mg, 100mg, or 150mg PO qday. Each subject will have at least three visits, including a screening/baseline visit, a two-week follow-up, and a four-week follow-up. The initial diagnosis will be made by a board-certified dermatologist or a dermatology-certified nurse practitioner. The Perioral Dermatitis Severity Index, PODSI, (Appendix I) will be used to grade the severity of periorificial dermatitis throughout the three visits. This published scoring method ranges from 0 to 9. To be included in the study, patients must need to have a PODSI score of moderate (PODSI = 3.0-5.5) or severe (PODSI = 6.0-9.0) at baseline. The primary endpoint is the percentage of patients that receive a PODSI score ranging from 0 (none) to 2.5 (mild) at week four. The secondary endpoint is the patient reported an adverse event at week four.
Study NCT04824027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harmonic motion imaging
Description: Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.
Study NCT03827187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery based EEG-BCI
Description: Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
Study NCT06640361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Oral administration with meal, QOD, every 28 days for a cycle.
Study NCT05239741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT05539287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus-Based Capsule
Description: 25 patients will receive Lactobacillus species 5 billion colonies forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
Study NCT05539287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus-Based Capsule
Description: 25 patients will receive Lactobacillus species 5 billion colonies forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
Study NCT05239741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
Study NCT05239741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
Study NCT05239741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
Study NCT05239741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
Study NCT05239741 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study NCT05239741 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: IV infusion
Study NCT06272643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography)
Description: OCT and IVUS in Patients with LMCA lesion (25-60%)
Study NCT06582745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.
Study NCT04485039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tecovirimat
Description: oral antiviral
Study NCT04485039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer carbonate oral tablet
Description: phosphate binder
Study NCT04485039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sucroferric oxyhydroxide chewable tablet
Description: phosphate binder
Study NCT04485039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: calcium acetate oral tablet
Description: phosphate binder
Study NCT04485039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lanthanum Carbonate Chewable Tablet
Description: phosphate binder
Study NCT06353321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET-CT imaging subsystem of the RefleXion X1 System Device
Description: Imaging performed only on the X1 platform immediately following already planned imaging using Illuccix for standard of care indications in men with prostate cancer of various stages, in order to assess performance of the X1 in comparison to diagnostic imaging scanners
Study NCT06109909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation
Description: The EEG interface device is a J\&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (\~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
Study NCT06109909 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation
Description: The EEG interface device is a J\&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (\~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
Study NCT06459791 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: The recommandation done based on informative tumorogram is up to study investigator
Study NCT06459791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: The recommandation done based on informative tumorogram is up to study investigator
Study NCT06511141 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Axonics SNM System
Description: To assess clinical outcomes of the Axonics SNM System in the male OAB population.
Study NCT05971719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Air Leaks: Aerosol glycerine System
Description: A range of different leak will be done with different needle sizes on the lung. Perform localization on staple lines used surgically during pulmonary surgeries, as they are known to not consistently give an airtight closure. The lung will be put in the ex-vivo model and ask for a surgeon to localize the leaks with our system. The needle incisions will be repeat on another lung and ask the same surgeon to localize the leaks with the submersion test. To perform the submersion test the surgeon will have to submerge the lung in saline solution and to check the presence of air bubbles. The lung is inflated to pressures of 20 to 40 cm H209. The precision of both systems will be compared by the minimal incision the minimal incision the surgeon was able to localize.
Study NCT04663087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XSTAT
Description: XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
Study NCT04663087 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: As currently provided by EMS services
Study NCT05636111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by (IV) vein
Study NCT05636111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by (IV) vein
Study NCT05636111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given by (IV) vein
Study NCT05848258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally
Study NCT05848258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05934370 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home-Based Environmental Interventions (HEI)
Description: Housing Specialist will conduct an environmental home assessment to identify asthma triggers.~• The participant will receive the following Breath Easy at Home Kit Products:~* HEPA filtered upright vacuum cleaner~* HEPA-filtered air purifier~* Hypoallergenic latex free mattress and pillow covers~* Healthier household cleaners~* Non-toxic pest control devices for rodent control~* Safe products to locate and kill roaches.
Study NCT05808101 — intervention group
Intervention type: OTHER
Intervention: Neuro-QoL T-score determination
Description: Neuro-Qol depression scale, using a T-score of 55 as a threshold
Study NCT05926180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)
Description: Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
Study NCT04669171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2463
Description: Multiple dose of EO2463
Study NCT04669171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: D1-21 of 4-weekly cycles
Study NCT04669171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Multiple doses of rituximab
Study NCT04895631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluorocholine
Description: One-time injection of 4-7 millicurie (mCi)
Study NCT04895631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
Study NCT06561698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium competitive acid blocker
Study NCT06561698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication
Study NCT06561698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT06561698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline,Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT05545761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
Study NCT05681962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).
Study NCT05095818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP-RN
Description: Patients randomized to the intervention arm will be counseled on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP (Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg).
Study NCT06115733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib、Capecitabine Tablets
Description: Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression.
Study NCT05356858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: zanubrutinib orally, 80mg bid for 1 year
Study NCT05227742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive oral psilocybin once per week for 5 weeks.
Study NCT05227742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive inert placebo once per week for 5 weeks.
Study NCT05656950 — intervention group
Intervention type: PROCEDURE
Intervention: Assessment
Description: Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
Study NCT05761860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oxycodone 5mg oral administration
Study NCT05761860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 2.5 mg Oral Tablet
Description: Oxycodone 2.5mg oral administration
Study NCT05761860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oxyCODONE Oral Tablet
Description: Oxycodone 0mg (placebo) oral administration
Study NCT05761860 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo oxyCODONE Oral Tablet
Description: Oxycodone 0mg (placebo) oral administration
Study NCT05761860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Nasal Spray (48 IU)
Description: Intranasal oxytocin administration (48 IU)